EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)

Urska Janzic, Natalie Maimon Rabinovich, Walid Shalata iD, Waleed Kian iD, Katarzyna Szymczak, Rafal Dziadziuszko, Marko Jakopovic iD, Giannis Mountzios iD, Adam Pluzanski iD, Antonio Araujo iD, Andriani Charpidou, Sameh Daher und 1 weitere

Current Oncology · 2024

DOI: 10.3390/curroncol31080326 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Current Oncology, 2024. Verfasst von Urska Janzic und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Protein-Tyrosine Kinases, Lung Neoplasms, Proto-Oncogene Proteins. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

ROS1 rearrangements are considered rare in non-small-cell lung cancer (NSCLC). This retrospective real-world study aimed to evaluate first-line treatment with crizotinib, a tyrosine kinase inhibitor (TKI) standard of care vs. new generation ROS1 anti-cancer agents. Forty-nine ROS1-expressing NSCLC patients, diagnosed with advanced metastatic disease, were included. Molecular profiling using either FISH/CISH or NGS was performed on tissue samples. Twenty-eight patients were treated with crizotinib, while fourteen patients were administered newer drugs (entrectinib, repotrectinib) and seven patients received platinum-doublet chemotherapy in a first-line setting. Overall response rate and disease control rate for the crizotinib and entrectinb/repotrectinib cohort were 68% and 82% vs. 86% and 93%, respectively. Median progression free survival was 1.6 years (95% CI 1.15–2.215) for the crizotinib treatment vs. 2.35 years for the entrectinib/repotrectinib cohort (95% CI 1.19–3.52). Central nervous system progression was noted in 20% and 25% of the crizotinib and entrectinib/repotrectinib cohorts, respectively. This multi-center study presents real-world treatment patterns of ROS1 NSCLC population, indicating that crizotinib exhibited comparable results to entrectinib/repotrectinib in a first-line setting, although both response rate and survival was numerically longer with treatment with newer agents.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungProtein-Tyrosine KinasesLung NeoplasmsProto-Oncogene ProteinsGene RearrangementHumansFemaleMiddle AgedMaleAgedRetrospective StudiesAdultAged, 80 and overCrizotinibProtein Kinase Inhibitors

Stichwörter der Autor:innen

ROS1 rearrangementsfirst-line treatmentnon-small-cell lung cancerreal-world data

Substanzen

ROS1 protein, humanProtein-Tyrosine KinasesProto-Oncogene ProteinsCrizotinibProtein Kinase Inhibitors

Autor:innen und Institutionen

  • Department of Medical Oncology, University Clinic Golnik, 4204 Golnik, Slovenia.
  • Medical Faculty Ljubliana, University of Ljubliana, 1000 Ljubljana, Slovenia.
  • Lung Oncology Service, Division of Oncology, Meir Medical Center, Sackler School of Medicine, Tel Aviv University, Kfar Saba 4428163, Israel.
  • The Legacy Heritage Cancer Center & Dr. Larry Norton Institute, Soroka Medical Center, Ben Gurion University, Beer Sheva 84105, Israel.
  • Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem 9436008, Israel.
  • Department of Oncology and Radiotherapy and Early Phase Clinical Trials Center, University of Gdańsk, 80-210 Gdańsk, Poland.

ORCID-Profile: Walid Shalata, Waleed Kian, Marko Jakopovic, Giannis Mountzios, Adam Pluzanski, Antonio Araujo, Abed Agbarya

Zitieren

APA

Janzic, U., Maimon Rabinovich, N., Shalata, W., Kian, W., Szymczak, K., Dziadziuszko, R., Jakopovic, M., Mountzios, G., Pluzanski, A., Araujo, A., Charpidou, A., Daher, S., & Agbarya, A. (2024). Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study). Current Oncology. https://doi.org/10.3390/curroncol31080326

Vancouver

Janzic U, Maimon Rabinovich N, Shalata W, Kian W, Szymczak K, Dziadziuszko R, et al. Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study). Current Oncology. 2024. doi:10.3390/curroncol31080326

BibTeX
@article{Janzic2024,
  author = {Janzic, Urska and Maimon Rabinovich, Natalie and Shalata, Walid and Kian, Waleed and Szymczak, Katarzyna and Dziadziuszko, Rafal and Jakopovic, Marko and Mountzios, Giannis and Pluzanski, Adam and Araujo, Antonio and Charpidou, Andriani and Daher, Sameh and Agbarya, Abed},
  title = {Non-Small-Cell Lung Cancer Patients Harboring ROS1 Rearrangement: Real World Testing Practices, Characteristics and Treatment Patterns (ROS1REAL Study)},
  journal = {Current Oncology},
  year = {2024},
  doi = {10.3390/curroncol31080326}
}
Kostenlos starten →